AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01652495
Drug: methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
Trial: NCT01652495
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
Trial: NCT02172144
Drug: Moxifloxacin (Avalox®)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00825123
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine 10 mg once
Trial: NCT00825123
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg once
Trial: NCT04102618
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose of 2.5 mg/day starting on Day 3 for 13 days
Trial: NCT04102618
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg administered intravenously on Day 3
Trial: NCT04102618
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Trial: NCT00044291
Drug: atamestane
RxNorm normalized name: Atamestane
DrugBank: Atamestane (DB12194)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00044291
Drug: toremifene
RxNorm normalized name: Toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00044291
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01811732
Drug: Delafloxacin
RxNorm normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delafloxacin
Trial: NCT01811732
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin
Trial: NCT01811732
Drug: Aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam
Trial: NCT03675646
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of 250 mcg preservative-free morphine before surgery
Trial: NCT00048035
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Differing doses and frequencies of iv administration
Trial: NCT02076685
Drug: isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose adjustment according to the pharmacogenomic results
Trial: NCT00346957
Drug: Anecortave acetate 30 mg
RxNorm normalized name: acetic acid 30 MG/ML
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml administered onto the sclera once every six months for 24 months
Trial: NCT00346957
Drug: Anecortave Acetate 15 mg
RxNorm normalized name: leuprolide acetate 15 MG/ML
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml administered onto the sclera once every six months for 24 months
Trial: NCT00346957
Drug: Anecortave Acetate 3 mg
RxNorm normalized name: Estradiol 3-acetate
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml administered onto the sclera once every six months for 24 months
Trial: NCT01611623
Drug: SNX-5422
RxNorm normalized name: SNX-5422
DrugBank: SNX-5422 (DB06070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets dose every other day; dose escalation based on safety
Trial: NCT02603198
Drug: mepivacaine chloridrato levonordefrin
RxNorm normalized name: levonordefrin / mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthesia for tooth removal
Trial: NCT00354965
Drug: amoxicillin/clavulanate potassium
RxNorm normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin/clavulanate potassium
Trial: NCT03534661
Drug: Teduglutide + Normal Saline
RxNorm normalized name: NS-2359
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
Trial: NCT03534661
Drug: Teduglutide + L-NMMA
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
Trial: NCT03534661
Drug: Placebo + L-NMMA
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
Trial: NCT02415153
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00774475
Drug: comparison of different dosage of clopidogrel
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel 75 mg/day versus clopidogrel 150 mg/day
Trial: NCT01867775
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg, at night, once a day for 14 days
Trial: NCT00963508
Drug: Malathion gel 0.5%
DrugBank: Malathion (DB00772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
Trial: NCT01951144
Drug: PF-06372865 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
Trial: NCT01951144
Drug: PF-06372865 or Placebo or Lorazepam
RxNorm normalized name: edaravone
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
Trial: NCT00037050
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037050
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037050
Drug: Oxacillin
RxNorm normalized name: Oxacillin
DrugBank: Oxacillin (DB00713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037050
Drug: Dicloxacillin
RxNorm normalized name: Dicloxacillin
DrugBank: Dicloxacillin (DB00485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03262077
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation with low-level laser for 1, 3, and 5 min
Trial: NCT03262077
Drug: Methylene Blue Oral Product
RxNorm normalized name: methylene blue Oral Product
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation with low-level laser for 1, 3, and 5 min
Trial: NCT00643201
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
Trial: NCT00643201
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Trial: NCT00643201
Drug: Placebo for apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
Trial: NCT00643201
Drug: Placebo for enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
Trial: NCT00643201
Drug: Placebo for warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
Trial: NCT00643201
Drug: apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Trial: NCT02976519
Drug: BI 443651
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT03266900
Drug: 6 weeks BCG instillation
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard 6 weeks of BCG induction
Trial: NCT00483652
Drug: Fampridine-SR
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10 mg, twice daily, 9 weeks
Trial: NCT01304797
Drug: MM-302 Monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of MM-302 as a single agent
Trial: NCT01304797
Drug: MM-302 in combination with trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
Trial: NCT00306904
Drug: bevasiranib
RxNorm normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00963508
Drug: Permethrin 1% rinse (Nix Crème)
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
Trial: NCT01304797
Drug: MM-302 in combination with trastuzumab q3w
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
Trial: NCT01304797
Drug: MM-302 in combination with trastuzumab and cyclophosphamide
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
Trial: NCT02654639
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 Twice a day by mouth day 1-5 and 8-12
Trial: NCT02654639
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab by intravenous infusion once every 14 days
Trial: NCT00407225
Drug: Difluprednate Ophthalmic Emulsion
RxNorm normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00716456
Drug: erlotinib with cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
Trial: NCT02640976
Drug: Human menopausal gonadotrophin (HMG)
RxNorm normalized name: human menopausal gonadotrophin
DrugBank: Menotropins (DB00032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Merional® 75 IU ampoules, IBSA institut\]
Trial: NCT00324922
Drug: trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: trimethoprim/sulfamethoxazole 320/1600 mg po bid
Trial: NCT00324922
Drug: vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g iv bid
Trial: NCT02640976
Drug: GnRH antagonist Cetrorelix
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[Cetrotide® 0.25 mg syringes, Merck Serono\]
Trial: NCT02640976
Drug: Human chorionic gonadotrophin (hCG)
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Choriomon® 5000 IU ampoules, IBSA institut\]
Trial: NCT00124683
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00124683
Drug: nicotine transdermal patch
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02689843
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg three times daily
Trial: NCT02689843
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30mg once daily
Trial: NCT00202917
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00202917
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00202917
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00202917
Drug: OKT-3
RxNorm normalized name: Oktafluorpropan
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02926898
Drug: ZX008 (Fenfluramine Hydrochloride)
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~\*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.
Trial: NCT02659943
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
Trial: NCT00371735
Drug: chlorproguanil-dapsone-artesunate
RxNorm normalized name: Artesunate
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00371735
Drug: chlorproguanil-dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02396329
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02396329
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04560010
Drug: Tranexamic Acid Injection (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later
Trial: NCT01023880
Drug: CEP-18770
RxNorm normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
Trial: NCT03583567
Drug: Chlorpheniramine and ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
Trial: NCT00942305
Drug: Brincidofovir
RxNorm normalized name: Brincidofovir
DrugBank: Brincidofovir (DB12151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
Trial: NCT01297686
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area.
Trial: NCT01895985
Drug: Latanoprostene bunod
RxNorm normalized name: Latanoprostene bunod
DrugBank: Latanoprostene bunod (DB11660)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00181870
Drug: carbamazepine ER (Equetro)
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03264911
Drug: Amoxicillin or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
Trial: NCT04144101
Drug: Aceclofenac
RxNorm normalized name: Aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg BID Oral
Trial: NCT03097484
Drug: lavender and chamomile essential oils
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Trial: NCT00039182
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00629733
Drug: RO-14
RxNorm normalized name: Dihydro-14-hydroxycodeinone
DrugBank: (5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE (DB08346)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02491515
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: every 6 month injection
Trial: NCT00367393
Drug: Pimecrolimus cream 1%
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% bid, as needed
Trial: NCT02884908
Drug: Pregabalin plus BBCET
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
Trial: NCT03820206
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
Trial: NCT00334672
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00334672
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00334672
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00334672
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00334672
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03212716
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg twice a day during 10 days (ANSM guidelines for severe flu).
Trial: NCT03212716
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mgx3 per day during 10 days.